Jeanette Dupont Jensen
Affiliation: Odense University Hospital
- PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumabJ D Jensen
Department of Oncology, Odense University Hospital, and Institute of Clinical Research, University of Southern Denmark, Odense, Denmark
Ann Oncol 23:2034-42. 2012....
- ER, HER2, and TOP2A expression in primary tumor, synchronous axillary nodes, and asynchronous metastases in breast cancerJeanette Dupont Jensen
Department of Oncology, Odense University Hospital, Sdr Boulevard 29, 5000 Odense, Denmark
Breast Cancer Res Treat 132:511-21. 2012..Expression of ER, HER2, and TOP2A displayed discordance with a sufficient frequency to emphasize the role of confirmatory biopsies from metastatic lesions in future management of recurrent breast cancer...
- PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancerJeanette Dupont Jensen
Department of Oncology, Odense University Hospital, Odense, Denmark
Clin Cancer Res 17:667-77. 2011..We wished to discern whether selective pressures occur and the influence of PIK3CA mutation on time to recurrence...